Technetium-99m labeled renal function and imaging agents: III. Synthesis of 99mTc-MAG3 and biodistribution of by-products.
99mTc-MAG3, a new 99mTc radiopharmaceutical with biological properties similar to o-iodohippuric acid (OIH), is expected to find wide clinical application for renal function studies. Therefore it is important to make a kit formulation available which provides reproducibly the desired product in high radiochemical yields. Some differences between the biokinetic data of kit prepared 99mTc-MAG3 and HPLC-purified 99mTc-MAG3 were reported by different authors. The subject of this paper is the isolation of the by-products which are formed with our own kits, the evaluation of their biological behaviour and the comparison with the main product 99mTc-MAG3 in rats. The results suggest that the radiochemical purity of 99mTc-MAG3-preparations should be not less than 95%.
Brandau
W
W
Klinikum der Universität Heidelberg, Zentrum Radiologie, F.R.G.
Bubeck
B
B
Eisenhut
M
M
Taylor
D M
DM
D000818:Animals; D005260:Female; D007553:Isotope Labeling; D007668:Kidney / Q000000981:diagnostic imaging*; D009842:Oligopeptides / Q000138:chemical synthesis* / Q000302:isolation & purification / Q000493:pharmacokinetics; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000302:isolation & purification / Q000493:pharmacokinetics; D011866:Radioisotope Renography; D051381:Rats; D011933:Reagent Kits, Diagnostic / Q000592:standards; D013667:Technetium / Q000302:isolation & purification / Q000493:pharmacokinetics; D017263:Technetium Tc 99m Mertiatide
D009842:Oligopeptides; D009942:Organometallic Compounds; D011933:Reagent Kits, Diagnostic; D017263:Technetium Tc 99m Mertiatide; D013667:Technetium